Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Filings indexed 793 across all filing types
Latest filing 2024-07-19 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-07-19 English
FORM 4
Director's Dealing
2024-07-19 English
FORM 4
Director's Dealing
2024-07-19 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) on July 19, 2024. It is a registration statement under the Securities Act of 1933, used by companies planning an initial public offering (IPO) or other securities offering. The text includes detailed information about the offering, selling stockholders, risk factors, use of proceeds, and other disclosures typical of an S-1 filing. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, supporting a high confidence level.
2024-07-19 English
FORM 4
Director's Dealing
2024-07-19 English
FORM 4
Director's Dealing
2024-07-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.